Evidence map›Paper›PMID 38312261›Full record

ReviewSkin health and disease2024

Prevalence and burden of vitiligo in Africa, the Middle East and Latin America.

Anwar Al Hammadi, Caio Cesar Silva de Castro, Nisha V Parmar, Javier Ubogui, Nael Hatatah, Haytham Mohamed Ahmed, Lyndon Llamado

Abstract readReview
In one paragraph

Review in Skin health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Incidence and prevalence of vitiligo by gender and age in the Colombian populationBiomedica : revista del Instituto Nacional de Salud · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. An Overview of the Biological Complexity of Vitiligo.Oxidative medicine and cellular longevity · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anwar Al HammadiDermamed Clinic Dubai United Arab Emirates.
Caio Cesar Silva de CastroDepartment of Dermatology Pontifícia Universidade Católica do Paraná Curitiba Brazil.
Nisha V ParmarDepartment of Dermatology Rashid Hospital Dubai United Arab Emirates.ORCID https://orcid.org/0000-0001-9732-9993
Javier UboguiPsoriahue Medicina Interdisciplinaria Buenos Aires Argentina.
Nael HatatahKing Salman Hospital Riyadh Saudi Arabia.
Haytham Mohamed AhmedPfizer Dubai United Arab Emirates.ORCID https://orcid.org/0000-0002-2883-3317
Lyndon LlamadoPfizer Makati Philippines.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is a common chronic autoimmune disorder characterized by skin and hair depigmentation that affects 0.5%-2.0% of the global population. Vitiligo is associated with diminished quality of life (QoL) and psychosocial burden. The burden of vitiligo may vary based on skin tone and cultural differences as well as geographical variations in disease awareness, societal stigma, healthcare systems and treatment options. Data on the burden and management of vitiligo in Africa, the Middle East and Latin America are scarce. Literature searches using terms covering vitiligo in Africa, the Middle East and Latin America were conducted using PubMed to identify relevant publications that focused on disease prevalence and burden, QoL and psychosocial impact and disease management between 2011 and 2021. Most of the reviewed studies were conducted in the Middle East, and most Latin American studies were from Brazil. Most studies involved small patient numbers and may not be generalizable. Reported prevalence of vitiligo ranged from 0.18% to 5.3% in Africa and the Middle East, and from 0.04% to 0.57% in Latin America. In several studies, prevalence was higher among female participants. Generally, non-segmental vitiligo was the dominant clinical variant identified and the age at onset varied widely across studies. Common comorbidities include autoimmune diseases such as Hashimoto's thyroiditis, alopecia areata and diabetes. Few treatment guidelines exist in these regions, with the exceptions of guidelines published by the Brazilian and Argentinian Societies of Dermatology. There is a clear unmet need for large epidemiological studies with uniform methodology to accurately ascertain the true prevalence of vitiligo in Africa, the Middle East and Latin America. Additional data on vitiligo burden and management in Africa and Latin America are also needed, along with local disease management guidelines that consider genetic variation, psychosocial burden and socioeconomic diversity in all 3 regions.

Identifiers

PMID38312261
PMCPMC10831562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.